]>Reaction of the Anticancer Organometallic Ruthenium Compound, [(<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msup><mml:mi>η</mml:mi><mml:mn>6</mml:mn></mml:msup></mml:mrow><mml:mtext>-</mml:mtext><mml:mi>p</mml:mi></mml:math>-Cymene)Ru(ATSC)Cl]<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mtext>PF</mml:mtext><mml:mtext>6</mml:mtext></mml:msub></mml:math> with Human Serum Albumin : Figure 8
975756.fig.008
Figure 8: FT-IR spectra of (a) free HSA and (b) the difference spectrum of HSA obtained by subtracting the spectrum of the metal complex from that of the metal complex-HSA solution. [HSA] = [Ru] = 3  𝜇 M; 24-hour incubation.